Biocon has struck a deal with Saudi firm Tabuk Pharmaceutical Manufacturing Company that will see the Indian company’s GLP-1 diabetes and chronic weight management products commercialized by Tabuk in “select countries” in the Middle East.
The agreements builds on an existing alliance between Biocon and Tabuk for generics, struck back in 2021 (see sidebar), which Biocon said at the time would pave the way for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?